PNC-27
p53-derived membrane-disrupting peptide
A p53 fragment fused to a penetratin sequence, studied in cancer cell models for selective membrane lysis.
How it works
Binds HDM-2 expressed on the membrane of transformed cells and forms pores, causing necrosis in those cells while sparing cells that lack membrane HDM-2.
What research has shown
In vitro and xenograft studies report tumor cell death with limited effect on normal cell lines. No human trials are published.
Reported ranges in the literature
Low end
Cell-model concentrations only
Optimal
No established human range
High end
Not characterized in humans
Frequency reported in the literature: Not established. Note: Preclinical research compound with no human dosing literature.
Protocol duration and pairing
Typical study duration
Preclinical work uses short 1 to 4 week exposures.
Best paired with
Studied on its own. No established pairing appears in the literature.
Oncology research compound with no established pairing literature.
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.